“Efficacy of Rifaximin in Diarrhoea Predominant Irritable Bowel Syndrome: A Placebo Controlled Clinical Trial”, Med. Today, vol. 35, no. 1, pp. 44–48, Apr. 2023, doi: 10.3329/medtoday.v35i1.64940.